Urgent warning issued for Ozempic after GLP-1 drugs linked to suicide
New precautions added for GLP-1 drugs as reports of mood changes and contraceptive concerns emerge in Australia.
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.
4 innovative ways to serve GLP-1 users – for today and tomorrow
Discover four innovative ways food and beverage brands are catering to GLP-1 users — from slow-release nutrition to high-protein drinks and gut health solutions.
Eli Lilly: The GLP-1 Leader’s Sky-High P/E Makes It A Clear Hold
‘There’s never been a drug with this range’: The weight loss boom is just getting started
New pill versions of weight loss drugs, lower prices, and patent expirations will all drive GLP-1 demand in 2026
Urgent health warning is issued over a disturbing side-effort linked to trendy new weight loss drugs like Ozempic
The Therapeutic Goods Administration issued a new warning for GLP-1 receptor agonists, including Ozempic and Mounjaro, on Monday.
Mental health warning issued for weight-loss drugs including Ozempic in Australia
TGA also issues separate warning around Mounjaro and potential reduced effectiveness of contraception The medicines regulator has added two new safety warnings around mental health and contraception for people taking high profile diabetes and weight loss drugs. The Therapeutic Goods Administration (TGA) says because suicidal behaviour and ideation have been reported with these relatively new […]
Watchdog issues safety alert for Ozempic and other GLP-1 drugs
The high-profile weight loss and diabetes drugs will come with two new warnings for patients.
Warning over new fat jab side effect that could hit up to three million Brits this Christmas
CHRISTMAS will be very merry for three million fat jab users — as they are likely to get drunk quickly. Doctors have issued a festive drink warning to those using GLP-1 drugs such as Mounjaro and Ozempic. They say users will get tipsy faster and that alcohol will stay in their systems for longer, increasing…
A weight loss pill that works like Ozempic? Early data on orforglipron sparks major buzz
A new oral GLP-1 receptor agonist, orforglipron, is revolutionizing weight management by offering a needle-free alternative to injectables. Clinical trials show significant weight loss and metabolic improvements, mirroring injectable efficacy. This convenient daily tablet promises better adherence and broader accessibility for individuals seeking effective obesity care, marking a significant shift in treatment delivery.